The malaria product pipeline: planning for the future

[1]  R. Anders,et al.  Integral membrane protein located in the apical complex of Plasmodium falciparum , 1989, Molecular and cellular biology.

[2]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[3]  M. Struck.  Chances and risks of developing vaccines. , 1996, Vaccine.

[4]  L. Miller,et al.  Identification of surface proteins on viable Plasmodium knowlesi merozoites. , 1981, The Journal of protozoology.

[5]  J. Duggan,et al.  A Strategic Vaccine Facility for the UK , 2005, Vaccine.

[6]  G. Corradin.  Peptide based malaria vaccine development: personal considerations. , 2007, Microbes and infection.

[7]  B. Greenwood.  Malaria vaccines. Evaluation and implementation. , 2005, Acta tropica.

[8]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[9]  N. Petrovsky.  Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. , 2006, Vaccine.

[10]  Bruce Neal,et al.  Priority medicines for Europe and the world , 2004 .

[11]  R. Ellis.  Product development plan for new vaccine technologies. , 2001, Vaccine.

[12]  E. Nardin,et al.  Stage-specific antigens on the surface membrane of sporozoites of malaria parasites , 1978, Nature.

[13]  M. Pirmohamed,et al.  Beyond registration--measuring the public-health potential of new treatments for malaria in Africa. , 2006, The Lancet. Infectious diseases.

[14]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[15]  T. Richie,et al.  Progress and challenges for malaria vaccines , 2002, Nature.

[16]  S. Glickman,et al.  A Portfolio Model of Drug Development for Tuberculosis , 2006, Science.